12 results about "Tissue fibrosis" patented technology

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The application provides a traditional Chinese medicine external application method for reducing the risk of fistula fibrosis in dialysis patients, relates to the technical field of clinical application of traditional Chinese medicine, is suitable for the prevention of autologous arteriovenous fistula fibrosis of maintenance hemodialysis patients, can effectively reduce the incidence of complications such as fistula peripheral tissue fibrosis and vascular stenosis, and prolongs the service life of the fistula. The drug stability and skin permeability are improved through optimization of adjuvants, and based on the grouping intervention of maintenance hemodialysis patients, the fistula blood flow and fibrosis improvement are evaluated in combination with color Doppler ultrasound. The application takes the principles of promoting blood circulation to remove blood stasis, dredging collaterals and resolving knots, and detoxification and swelling reduction as the therapeutic principles, prepares a fistula protection ointment by screening and optimizing a traditional Chinese medicine formula, realizes the effects of improving local microcirculation of the fistula, inhibiting fibrous tissue proliferation and reducing inflammatory reactions through external application intervention, thereby reducing the incidence of fistula fibrosis and related complications, prolonging the fistula patency time, simultaneously reducing the treatment cost, and improving the patient tolerance and life quality.

This invention discloses a method for constructing a PBMC-derived humanized mouse scleroderma model. Human peripheral blood mononuclear cells are transplanted into immunodeficient mice, and a human immune system is reconstructed in the mice. Bleomycin is injected into the local skin of the mice in a round-point manner to induce fibrosis and form a scleroderma model. This application can more comprehensively simulate the complex pathological process of immune abnormalities and tissue fibrosis coexisting in human scleroderma, and provides a more realistic and systematic experimental platform for in-depth exploration of the immune mechanism of this disease.

Disclosed herein are methods of treatment for diseases and disorders with modulators of full-length or thrombin-cleaved osteopontin. Particularly disclosed herein are methods comprising treatment of tissue fibrosis (e.g., pulmonary, cardiac, liver, kidney, skin) with antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin.

A fibrosis measurement device that measures fibrosis of a biological tissue non-invasively includes: a sound wave emitter that performs scanning over a surface of a biological tissue as a measurement object to emit sound waves; an electromagnetic wave receiver that receives an electromagnetic wave generated at each location of a biological tissue irradiated with sound waves; a signal extractor that extracts a signal indicating physical property, based on at least one selected from a group including the amplitude, phase, and frequency of an electromagnetic wave received by the electromagnetic wave receiver; an imaging unit that images signals extracted by the signal extractor; and an area comparison unit that compares the area of a portion of the two-dimensional image in which signals indicating a property are displayed, with an area corresponding to a preset threshold of the strength of the signals.

This invention relates to the field of nanobiomedicine, and discloses a method for preparing resveratrol-loaded europium-doped layered double hydroxide nanomaterials and their applications. First, using LDH as a base nanocarrier, europium ions are introduced to dope the LDH layered structure, forming Eu-LDH nanomaterials. LDH consists of positively charged metal hydroxide layers with tunable interlayer spaces. Utilizing the layered structure, bioactive resveratrol molecules can be stably loaded into the interlayer structure through intercalation or adsorption, thereby forming an REu-LDH nanocomposite system. This structure improves the stability and bioavailability of resveratrol while achieving slow drug release. The resulting nanomaterials can be used to prepare drugs to alleviate radiation-induced lung injury, reducing radiation-induced oxidative stress damage, inhibiting the release of inflammatory factors and regulating immune responses, and delaying or inhibiting the progression of pulmonary fibrosis.

This invention discloses the application of daidzein A in the preparation of anti-fibrotic drugs. This invention is the first to propose and verify that daidzein A can effectively inhibit ferroptosis, restore renal cell activity, downregulate the expression of fibrosis-related proteins, alleviate collagen deposition, reduce kidney damage, and effectively curb the progression of renal fibrosis, providing a new option with clinical translational potential for the treatment of renal fibrosis.

The application discloses a kind of for removing apoptotic cell, inhibiting the mechanical adaptive hydrogel of tissue fibrosis and preparation method and application thereof, and the hydrogel includes interpenetrating network polymer matrix and dynamic nanocomposite embedded in matrix.The hydrogel of the application provides structural support with AAm as the first crosslinking network, CSMA is given softness and high porosity connectivity as the second network, realizes high bearing and self-adaptive deformation to external pulling.The CP@ZV as nanonode, through the network stability of multiple-point non-covalent interaction is enhanced and the pulling energy generated by pre-stretching is dissipated.After pre-stretching attachment, nanonode cooperatively forms reverse mechanical buffer, effectively reduces the abnormal pulling stress perceived by edge cell, inhibits mechanical signal sustained activation, so as to restore macrophage cytophagic-mediated apoptotic cell removal function.

This invention discloses the application of eugenol in the preparation of drugs for the treatment of tissue fibrosis. This invention is the first to propose and verify that eugenol can inhibit ferroptosis in lung epithelial cells, thereby inhibiting the migration of fibroblasts and downregulating the expression of fibrosis-related proteins, thus effectively alleviating the progression of fibrosis and providing a new direction for the treatment of tissue fibrosis, especially pulmonary fibrosis.

As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).

The application belongs to the technical field of biomedicine, and specifically discloses a kind of enabled mesenchymal stem cells, enabled mesenchymal stem cell composition and its application in preparation treatment organ dysfunction drug, and the enabled mesenchymal stem cells are obtained by treating human mesenchymal stem cells with a kind of halogenated salicylic alcohol HEP14, and the enabled mesenchymal stem cell composition includes the enabled mesenchymal stem cells and HEP14 / PLGA microspheres with high HEP14 load and long-acting HEP14 sustained release prepared by using polylactic acid-hydroxyacetic acid copolymer (PLGA) as a carrier.The enabled mesenchymal stem cells of the application have the effects of strengthening mesenchymal stem cell survival viability and stemness, resisting tissue fibrosis, promoting tissue angiogenesis, promoting tissue regeneration and functional recovery;the combined application of the enabled mesenchymal stem cells and HEP14 / PLGA microspheres strengthens the retention and transdifferentiation of the enabled mesenchymal stem cells in the tissue, so the function of the enabled mesenchymal stem cells and the application in the field of regenerative medicine are further strengthened.